

## EQA round: IHC1/24 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 23.2.2024

Setup: groups - R (manufacturer of kit)

AV = assigned value

N<sub>tot</sub> = total number of the resultsN<sub>eva</sub> = number of the results assessedN<sub>rel</sub> = relative number of the resultsN<sub>suc</sub> = number of successful results

CVE = consensus of the experts

&gt;&gt;&gt; ... expected result

S<sub>rel</sub> = relative success

&gt; ... acceptable result

± ... result not assessed

Test Sample Group	Frequency of the results				Success		
	AV	N <sub>tot</sub>	N <sub>rel</sub> [%]	Result	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]
<b>(601) A1 expression HER-2/neu</b>		47			47	47	100
<b>Slide</b>		47			47	47	100
(802) Dako HercepTest	CVE >>>	8	17	Strong positive (3+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	11	23	Strong positive (3+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	26	55	Strong positive (3+)			
(999) another manufacturer	CVE >>>	2	4,3	Strong positive (3+)			
<b>(602) A2 expression HER-2/neu</b>		47			47	46	98
<b>Slide</b>		47			47	46	98
(802) Dako HercepTest	CVE >>>	3	6,4	Negative (0)			
	>	4	8,5	Negative (1+)			
		1	2,1	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	8	17	Negative (0)			
	>	3	6,4	Negative (1+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	26	55	Negative (0)			
(999) another manufacturer	CVE >>>	1	2,1	Negative (0)			
	>	1	2,1	Negative (1+)			
<b>(603) A3 expression HER-2/neu</b>		47			0		
<b>Slide</b>		47			0		
(0) not specified	±	1	2,1	Weak positive (2+)			
(802) Dako HercepTest	±	6	13	Weak positive (2+)			
	±	2	4,3	Strong positive (3+)			
(803) Dako c-erbB-2 Onkoprotein	±	10	21	Weak positive (2+)			
	±	1	2,1	Strong positive (3+)			
(804) Ventana PATHWAY anti-HER-2/neu	±	11	23	Negative (1+)			
	±	15	32	Weak positive (2+)			
(999) another manufacturer	±	1	2,1	Weak positive (2+)			
<b>(606) B1 expression HER-2/neu</b>		47			47	35	74
<b>Slide</b>		47			47	35	74
(802) Dako HercepTest		2	4,3	Negative (1+)			
	CVE >>>	6	13	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein		1	2,1	Negative (0)			
		1	2,1	Negative (1+)			
	CVE >>>	9	19	Weak positive (2+)			
(804) Ventana PATHWAY anti-HER-2/neu		7	15	Negative (1+)			
	CVE >>>	19	40	Weak positive (2+)			
(999) another manufacturer		1	2,1	Negative (1+)			
	CVE >>>	1	2,1	Weak positive (2+)			
<b>(607) B2 expression HER-2/neu</b>		47			47	47	100
<b>Slide</b>		47			47	47	100
(802) Dako HercepTest	CVE >>>	7	15	Weak positive (2+)			
	>	1	2,1	Strong positive (3+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	10	21	Weak positive (2+)			
	>	1	2,1	Strong positive (3+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	24	51	Weak positive (2+)			
	>	2	4,3	Strong positive (3+)			
(999) another manufacturer	CVE >>>	2	4,3	Weak positive (2+)			
<b>(608) B3 expression HER-2/neu</b>		47			0		
<b>Slide</b>		47			0		
(802) Dako HercepTest	±	1	2,1	Negative (1+)			
	±	7	15	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	±	3	6,4	Negative (1+)			
	±	8	17	Weak positive (2+)			
(804) Ventana PATHWAY anti-HER-2/neu	±	1	2,1	Negative (0)			
	±	14	30	Negative (1+)			
	±	11	23	Weak positive (2+)			
(999) another manufacturer	±	2	4,3	Negative (1+)			
<b>(611) C1 expression HER-2/neu</b>		47			47	43	91
<b>Slide</b>		47			47	43	91
(802) Dako HercepTest	CVE >>>	7	15	Weak positive (2+)			
	>	1	2,1	Strong positive (3+)			
(803) Dako c-erbB-2 Onkoprotein		3	6,4	Negative (1+)			
	CVE >>>	7	15	Weak positive (2+)			
	>	1	2,1	Strong positive (3+)			
(804) Ventana PATHWAY anti-HER-2/neu		1	2,1	Negative (1+)			

## EQA round: IHC1/24 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 23.2.2024

Setup: groups - R (manufacturer of kit)

Test Sample Group	Frequency of the results				Success		
	AV	N <sub>tot</sub>	N <sub>rel</sub> [%]	Result	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]
	CVE >>>	24	51	Weak positive (2+)			
	>	1	2,1	Strong positive (3+)			
(999) another manufacturer	CVE >>>	2	4,3	Weak positive (2+)			
<b>(612) C2 expression HER-2/neu</b>		47			47	46	98
<b>Slide</b>		47			47	46	98
(802) Dako HercepTest	CVE >>>	1	2,1	Negative (0)			
	CVE >>>	6	13	Negative (1+)			
		1	2,1	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	5	11	Negative (0)			
	CVE >>>	6	13	Negative (1+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	22	47	Negative (0)			
	CVE >>>	4	8,5	Negative (1+)			
(999) another manufacturer	CVE >>>	1	2,1	Negative (0)			
	CVE >>>	1	2,1	Negative (1+)			
<b>(613) C3 expression HER-2/neu</b>		47			47	47	100
<b>Slide</b>		47			47	47	100
(802) Dako HercepTest	CVE >>>	6	13	Weak positive (2+)			
	>	2	4,3	Strong positive (3+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	10	21	Weak positive (2+)			
	>	1	2,1	Strong positive (3+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	25	53	Weak positive (2+)			
	>	1	2,1	Strong positive (3+)			
(999) another manufacturer	CVE >>>	2	4,3	Weak positive (2+)			
<b>(616) D1 expression HER-2/neu</b>		47			47	47	100
<b>Slide</b>		47			47	47	100
(802) Dako HercepTest	CVE >>>	6	13	Negative (0)			
	CVE >>>	2	4,3	Negative (1+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	5	11	Negative (0)			
	CVE >>>	6	13	Negative (1+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	16	34	Negative (0)			
	CVE >>>	10	21	Negative (1+)			
(999) another manufacturer	CVE >>>	2	4,3	Negative (0)			
<b>(617) D2 expression HER-2/neu</b>		47			0		
<b>Slide</b>		47			0		
(802) Dako HercepTest	±	3	6,4	Negative (1+)			
	±	5	11	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	±	4	8,5	Negative (1+)			
	±	7	15	Weak positive (2+)			
(804) Ventana PATHWAY anti-HER-2/neu	±	7	15	Negative (1+)			
	±	18	38	Weak positive (2+)			
	±	1	2,1	Strong positive (3+)			
(999) another manufacturer	±	2	4,3	Negative (1+)			
<b>(618) D3 expression HER-2/neu</b>		47			47	43	91
<b>Slide</b>		47			47	43	91
(802) Dako HercepTest	>	5	11	Negative (0)			
	CVE >>>	3	6,4	Negative (1+)			
(803) Dako c-erbB-2 Onkoprotein	>	8	17	Negative (0)			
	CVE >>>	3	6,4	Negative (1+)			
(804) Ventana PATHWAY anti-HER-2/neu	>	8	17	Negative (0)			
	CVE >>>	14	30	Negative (1+)			
		4	8,5	Weak positive (2+)			
(999) another manufacturer	>	1	2,1	Negative (0)			
	CVE >>>	1	2,1	Negative (1+)			
<b>(621) E1 expression HER-2/neu</b>		47			47	46	98
<b>Slide</b>		47			47	46	98
(802) Dako HercepTest	CVE >>>	5	11	Negative (0)			
	>	2	4,3	Negative (1+)			
		1	2,1	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	8	17	Negative (0)			
	>	3	6,4	Negative (1+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	25	53	Negative (0)			
	>	1	2,1	Negative (1+)			
(999) another manufacturer	CVE >>>	2	4,3	Negative (0)			
<b>(622) E2 expression HER-2/neu</b>		47			47	47	100
<b>Slide</b>		47			47	47	100
(802) Dako HercepTest	CVE >>>	8	17	Negative (0)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	10	21	Negative (0)			
	>	1	2,1	Negative (1+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	22	47	Negative (0)			

## EQA round: IHC1/24 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 23.2.2024

Setup: groups - R (manufacturer of kit)

Test Sample Group	Frequency of the results				Success		
	AV	N <sub>tot</sub>	N <sub>rel</sub> [%]	Result	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]
(999) another manufacturer	>	4	8,5	Negative (1+)			
(623) E3 expression HER-2/neu	CVE >>>	2	4,3	Negative (0)			
<b>Slide</b>		46			46	46	100
(802) Dako HercepTest	CVE >>>	8	17	Negative (0)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	11	24	Negative (0)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	25	54	Negative (0)			
	>	1	2,2	Negative (1+)			
(999) another manufacturer	>	1	2,2	Negative (1+)			